Authors:
Sutedja, TG
Venmans, BJ
Smit, EF
Postmus, PE
Citation: Tg. Sutedja et al., Fluorescence bronchoscopy for early detection of lung cancer - A clinical perspective, LUNG CANC, 34(2), 2001, pp. 157-168
Authors:
Vansteenkiste, JF
De Belie, B
Deneffe, GJ
Demedts, MG
De Leyn, PR
Van Raemdonck, DE
Lerut, TE
Citation: Jf. Vansteenkiste et al., Practical approach to patients presenting with multiple synchronous suspect lung lesions - A reflection on the current TNM classification based on 54cases with complete follow-up, LUNG CANC, 34(2), 2001, pp. 169-175
Citation: Sj. Lewis et al., Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population, LUNG CANC, 34(2), 2001, pp. 177-183
Authors:
Jimenez-Orozco, FA
Lopez-Gonzalez, JS
Nieto-Rodriguez, A
Velasco-Velaquez, MA
Molina-Guarneros, JA
Mendoza-Patino, N
Garcia-Mondragon, MJ
Elizalde-Galvan, P
Leon-Cedeno, F
Mandoki, JJ
Citation: Fa. Jimenez-orozco et al., Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin, LUNG CANC, 34(2), 2001, pp. 185-194
Authors:
Suzuki, Y
Yanagawa, H
Nishioka, Y
Nishimura, N
Takeuchi, E
Sone, S
Citation: Y. Suzuki et al., Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung cancer, LUNG CANC, 34(2), 2001, pp. 195-205
Authors:
Jin, ML
Inoue, S
Umemura, T
Moriya, J
Arakawa, M
Nagashima, K
Kato, H
Citation: Ml. Jin et al., Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II, LUNG CANC, 34(2), 2001, pp. 207-218
Authors:
Hara, H
Yamashita, K
Shinada, J
Yoshimura, H
Kameya, T
Citation: H. Hara et al., Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer, LUNG CANC, 34(2), 2001, pp. 219-226
Authors:
Potti, A
Ganti, AK
Koch, M
Mehdi, SA
Levitt, R
Citation: A. Potti et al., Identification of HER-2/neu overexpression and the clinical course of lungcarcinoma in non-smokers with chronic lymphocytic leukemia, LUNG CANC, 34(2), 2001, pp. 227-232
Authors:
Ushijima, C
Tsukamoto, S
Yamazaki, K
Yoshino, I
Sugio, K
Sugimachi, K
Citation: C. Ushijima et al., High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression, LUNG CANC, 34(2), 2001, pp. 233-241
Citation: H. Bozcuk et C. Martin, Does treatment delay affect survival in non-small cell lung cancer? A retrospective analysis from a single UK centre, LUNG CANC, 34(2), 2001, pp. 243-252
Authors:
Anacak, Y
Mogulkoc, N
Ozkok, S
Goksel, T
Haydaroglu, A
Bayindir, U
Citation: Y. Anacak et al., High dose rate endobronchial brachytherapy in combination with external beam radiotherapy for stage III non-small cell lung cancer, LUNG CANC, 34(2), 2001, pp. 253-259
Authors:
Novello, S
Galli, L
Antonuzzo, A
Crino, L
Pozzi, E
Selvaggi, G
Ricci, S
Marrocolo, F
Darwish, S
Sorbolini, S
Tonato, M
Scagliotti, GV
Citation: S. Novello et al., Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer, LUNG CANC, 34(2), 2001, pp. 261-269
Authors:
Clark, JI
Kancharla, K
Qamar, R
Fisher, S
Hantel, A
Panganiban, J
Millbrandt, L
Albain, KS
Citation: Ji. Clark et al., Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer, LUNG CANC, 34(2), 2001, pp. 271-277
Authors:
Ceresoli, GL
Locati, LD
Ferreri, AJM
Cozzarini, C
Passoni, P
Melloni, G
Zannini, P
Bolognesi, A
Villa, E
Citation: Gl. Ceresoli et al., Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma, LUNG CANC, 34(2), 2001, pp. 279-287
Citation: Mp. Kosty et al., High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study - Cancer and Leukemia Group B 9631, LUNG CANC, 34(2), 2001, pp. 289-295
Authors:
Montalar, J
Morales, S
Maestu, I
Camps, C
Vadell, C
Garcia, R
Yuste, AL
Torregrosa, D
Segura, A
Citation: J. Montalar et al., Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer, LUNG CANC, 34(2), 2001, pp. 305-311
Authors:
Jelic, S
Mitrovic, L
Radosavljevic, D
Elezar, E
Babovic, N
Kovcin, V
Tomasevic, Z
Kovacevic, S
Gavrilovic, D
Radulovic, S
Citation: S. Jelic et al., Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study, LUNG CANC, 34(1), 2001, pp. 1-13
Citation: T. Berghmans et al., Cisplatin or carboplatin for the treatment of non-small cell lung cancer: do they have equivalent efficacy?, LUNG CANC, 34(1), 2001, pp. 15-17
Authors:
van Dijck, JAAM
Festen, J
de Kleijn, EMHA
Kramer, GWPM
Tjan-Heijnen, VCG
Verbeek, ALM
Citation: Jaam. Van Dijck et al., Treatment and survival of patients with non-small cell lung cancer stage IIIA diagnosed in 1989-1994: a study in the region of the Comprehensive Cancer Centre East, The Netherlands, LUNG CANC, 34(1), 2001, pp. 19-27
Authors:
Ichinose, Y
Kato, H
Koike, T
Tsuchiya, R
Fujisawa, T
Shimizu, N
Watanabe, Y
Mitsudomi, T
Yoshimura, M
Citation: Y. Ichinose et al., Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the JapanClinical Oncology Group to plan for clinical trials, LUNG CANC, 34(1), 2001, pp. 29-36
Authors:
Sasaki, H
Chen, LB
Auclair, D
Moriyama, S
Kaji, M
Fukai, I
Kiriyama, M
Yamakawa, Y
Fujii, Y
Citation: H. Sasaki et al., Overexpression of Hrad17 gene in non-small cell lung cancers correlated with lymph node metastasis, LUNG CANC, 34(1), 2001, pp. 47-52
Authors:
Sasaki, H
Moriyama, S
Yukiue, H
Kobayashi, Y
Nakashima, Y
Kaji, M
Fukai, I
Kiriyama, M
Yamakawa, Y
Fujii, Y
Citation: H. Sasaki et al., Expression of the antiapoptosis gene, AAC-11, as a prognosis marker in non-small cell lung cancer, LUNG CANC, 34(1), 2001, pp. 53-57